Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2014 August 18, 2014 arGEN-X Announces Positive Preclinical Results for ARGX-113 August 10, 2014 arGEN-X Raises Additional €1.8 million via Exercise of Over-allotment Option and Announces the End of the Stabilization Period August 4, 2014 arGEN-X to Present at the Wedbush 2014 Life Sciences Management Access Conference July 7, 2014 arGEN-X Raises €40 million in successful Initial Public Offering on Euronext Brussels June 19, 2014 arGEN-X Launches Initial Public Offering on Euronext Brussels June 9, 2014 arGEN-X Announces Intention to Launch an Initial Public Offering on Euronext Brussels June 3, 2014 arGEN-X Enters Long-term Strategic Alliance with Shire Pharmaceuticals in Therapeutic Antibodies May 28, 2014 arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO May 27, 2014 arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates April 23, 2014 arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders April 6, 2014 arGEN-X uses its SIMPLE Antibody™ platform to identify four ‘hotspots’ on MET as targets for its therapeutic antibody program April 3, 2014 arGEN-X Appoints Dr Werner Lanthaler to its Supervisory Board Pagination First page « First Previous page ‹ Previous … Page 21 Page 22 Page 23 Page 24 Page 25 Current page 26 Page 27 Page 28 Page 29 Next page Next › Last page Last »
